UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside

By: via Benzinga
In a report published Thursday, UBS Securities analyst Andrew Peters reiterated a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN), ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.